Tarsier Pharma Files F-1 for IPO; Plans 5M Share Offering
Tarsier Pharma Ltd. has filed an amended F-1 registration statement for its initial public offering (IPO), aiming to raise capital for the development of its novel pharmaceutical therapies for blinding eye diseases. The company plans to offer 5,000,000 ordinary shares at an anticipated price range of $8.00 to $10.00 per share. Tarsier Pharma is developing TRS01 and TRS02, which target unmet needs in uveitis and uveitic glaucoma, and has secured a Special Protocol Assessment agreement with the FDA for its pivotal Phase 3 trial for TRS01. The company is leveraging its status as an emerging growth company and a foreign private issuer to utilize reduced disclosure requirements. A 10-for-1 forward stock split is planned before the offering closes.
Key Highlights
- Tarsier Pharma Ltd. filed an amended F-1 registration statement for an initial public offering.
- The company plans to offer 5,000,000 ordinary shares with an anticipated price range of $8.00 to $10.00 per share.
- Tarsier Pharma is developing TRS01 and TRS02, novel product candidates for uveitis and uveitic glaucoma.
- The company has secured a Special Protocol Assessment agreement with the FDA for its pivotal Phase 3 trial for TRS01.
- Tarsier Pharma is an emerging growth company and a foreign private issuer, utilizing reduced disclosure requirements.
- The company will effect a 10-for-1 forward stock split prior to the closing of the offering.
- The offering is underwritten on a firm commitment basis, with an option for the underwriter to purchase an additional 750,000 shares.
Price Impact
More from TARX